Loading…
Zymeworks Inc. is projected to rise to $33.71 by 2027, a +45% move from its current price of $23.26. ZYME is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 6/10/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jun 11 | $22.79 | $23.28 | $23.79 | +0.11% |
| Jun 12 | $22.62 | $23.31 | $24.02 | +0.21% |
| Jun 13 | $22.49 | $23.33 | $24.21 | +0.32% |
| Jun 14 | $22.39 | $23.36 | $24.37 | +0.43% |
| Jun 15 | $22.30 | $23.38 | $24.52 | +0.53% |
| Jun 16 | $22.22 | $23.41 | $24.66 | +0.64% |
| Jun 17 | $22.15 | $23.43 | $24.79 | +0.75% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.15 | $23.43 | $24.79 | +0.75% |
| Week 2 | $21.80 | $23.61 | $25.56 | +1.50% |
| Week 3 | $21.58 | $23.78 | $26.22 | +2.25% |
| Week 4 | $21.41 | $23.96 | $26.81 | +3.01% |
| Week 5 | $21.29 | $24.14 | $27.38 | +3.78% |
| Week 6 | $21.19 | $24.32 | $27.91 | +4.56% |
| Week 7 | $21.11 | $24.50 | $28.43 | +5.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zymeworks Inc. is a biotechnology company that develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. Its platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc.
Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Zymeworks Inc. is a biotechnology company focused on developing biotherapeutics for cancer, inflammation, and autoimmune diseases within the healthcare sector. The stock currently trades at $23.26 and has a market cap of $1.71B, ranking 2077.
The current price outlook aligns with a broader forecast that projects a path of higher potential prices over time, with 2026 forecasting an average price of $23.26 and a broad upside into the coming years. The multi-year forecast shows significant upside through 2050, with bullish sentiment returning strongly after 2026.
A major floor 10.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.7% away) — a key level to hold.
The nearest ceiling, 22.8% above — a clean break opens room to run.
A major ceiling 29.5% above — clearing it would confirm fresh momentum.
Key ZYME support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZYME market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.31 | Sell | $24.32 | Sell |
| MA 10 | $24.69 | Sell | $24.54 | Sell |
| MA 20 | $24.58 | Sell | $24.88 | Sell |
| MA 50 | $25.90 | Sell | $25.20 | Sell |
| MA 100 | $24.71 | Sell | $24.59 | Sell |
| MA 200 | $22.48 | Buy | $22.46 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.56 | Neutral |
| Stoch RSI (14) | 7.06 | Buy |
| CCI (20) | -90.62 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -3.66 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -1.40 | Sell |
| Ultimate (7,14,28) | 34.36 | Neutral |
| Momentum (10) | -1.68 | Sell |
| Aroon Osc (25) | -8.00 | Sell |
| Hull MA (9) | 24.19 | Sell |
| ADX (14) | 13.28 | Neutral |
| ATR (14) | 0.51 | Info |
The 30-day picture is bullish overall. RSI(14) is 40, with a near-term momentum bias toward higher prices. The 50-day simple moving average sits at $25.90, above the 200-day moving average of $22.48, indicating a positive intermediate trend.
A support level is noted at $23.89 and a resistance hurdle at $28.56. The 30-day price range spans from $20.22 to $26.76, reflecting a volatile yet constructive short-term trading window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.02 | $23.26 | $35.12 | 0% | Neutral | |
| $27.33 | $33.71 | $43.67 | +45% | Bullish | |
| $31.36 | $39.48 | $52.65 | +70% | Bullish | |
| $35.00 | $44.84 | $61.19 | +93% | Bullish | |
| $37.44 | $48.70 | $67.76 | +109% | Bullish | |
| $42.22 | $55.68 | $78.82 | +139% | Bullish | |
| $48.48 | $64.77 | $93.11 | +178% | Bullish | |
| $59.21 | $80.06 | $116.72 | +244% | Bullish | |
| $67.75 | $92.64 | $136.84 | +298% | Bullish | |
| $67.57 | $93.40 | $139.64 | +302% | Bullish | |
| $112.67 | $163.50 | $257.28 | +603% | Bullish | |
| $198.61 | $312.76 | $530.77 | +12.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| June 2026 | $22.02 | $23.26 | $28.58 | +0.00% |
| July 2026 | $21.48 | $25.21 | $30.27 | +8.37% |
| August 2026 | $21.71 | $25.62 | $31.04 | +1.65% |
| September 2026 | $22.35 | $26.50 | $32.33 | +3.41% |
| October 2026 | $23.44 | $27.90 | $34.26 | +5.28% |
| November 2026 | $23.75 | $28.36 | $35.02 | +1.68% |
| December 2026 | $23.61 | $28.29 | $35.12 | -0.25% |
Click any year to see its month-by-month ZYME forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Zymeworks Inc.'s 2026 outlook centres on $23.26, within a $22.02 to $35.12 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ZYME could reach as high as $43.67, with a base case around $33.71 and support toward $27.33 — roughly +45% from $23.26. Buyers look set to stay in control over this stretch.
Expect ZYME to range from $31.36 to $52.65 through 2028. The $39.48 average target implies a +70% move from current prices. That is up +17% on the projected 2027 average. Momentum favours further upside here.
The ZYME price prediction for 2029 points to an average of $44.84 (low $35.00, high $61.19) — a potential gain of +93% on today's $23.26. Buyers look set to stay in control over this stretch.
In 2030, ZYME is projected to trade between $37.44 and $67.76, averaging $48.70 — a potential gain of +109% from today's $23.26. That is up +9% on the projected 2029 average. Momentum favours further upside here.
Zymeworks Inc.'s 2031 outlook centres on $55.68, within a $42.22 to $78.82 range. That is up +14% on the projected 2030 average. That marks a +139% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ZYME could reach as high as $93.11, with a base case around $64.77 and support toward $48.48 — roughly +178% from $23.26. Momentum favours further upside here.
Expect ZYME to range from $59.21 to $116.72 through 2033. The $80.06 average target implies a +244% move from current prices. That is up +24% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ZYME price prediction for 2034 points to an average of $92.64 (low $67.75, high $136.84) — a potential gain of +298% on today's $23.26. Momentum favours further upside here.
In 2035, ZYME is projected to trade between $67.57 and $139.64, averaging $93.40 — a potential gain of +302% from today's $23.26. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Zymeworks Inc.'s 2040 outlook centres on $163.50, within a $112.67 to $257.28 range. That is up +75% on the projected 2035 average. That marks a +603% change versus current levels. Momentum favours further upside here.
By 2050, ZYME could reach as high as $530.77, with a base case around $312.76 and support toward $198.61 — roughly +12.4x from $23.26. Buyers look set to stay in control over this stretch.
Investing $1,000 in ZYME today (≈ 42.992261 ZYME) could be worth
$13,446.08
+$12,446.08 (+1245%) by 2050 · US Dollar
Based on the average projected ZYME price of $312.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZYMEwould be worth at today's price.
$1,000 invested in ZYME on Jun 9, 2025 (≈ 80.321286 ZYME) would be worth
$1,868.27
+$868.27 (+86.8%) today · 1.87× · US Dollar
Based on a ZYME entry price of $12.45 vs. today's $23.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24.54 | $947.84 | -5.2% |
| 1 month ago | $23.89 | $973.63 | -2.6% |
| 3 months ago | $25.46 | $913.59 | -8.6% |
| 6 months ago | $25.87 | $899.11 | -10.1% |
| 1 year ago | $12.45 | $1,868.27 | +86.8% |
| All time (5.0y) ago | $37.73 | $616.49 | -38.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZYME forecast.
Our base-case forecast reaches $47.00 around 2030.
Implied market cap at $47.00: $3.43B
The long-term forecast shows a strong upside trajectory with rising average prices and sizable ROI across key years. In 2030 the average forecast price is $48.70 with a 109.4% ROI and bullish sentiment. The 2040 forecast projects an average of $163.50 with a 602.9% ROI and bullish sentiment, while 2050 moves to an average of $312.76 with a 1244.6% ROI and bullish sentiment.
These are estimates, not guarantees, and reflect projected appreciation over time alongside ongoing bullish sentiment in later years. The path implies meaningful upside beyond 2026, contingent on market dynamics and company fundamentals as projected by the model.
Tap a question to reveal the answer.
20230 min $37.44, avg $48.70, max $67.76 with ROI 109.4% and bullish sentiment.
The forecast shows a switch from neutral in 2026 to bullish sentiment from 2027 onward, with average price rising from $23.26 in 2026 to $48.70 in 2030 and increasing further to $312.76 by 2050, yielding positive ROIs of 44.9% in 2027 up to 1244.6% in 2050. These are estimates, not guarantees.
The 2040 forecast shows an average price of $163.50 with a 602.9% ROI and bullish sentiment.
The 2050 forecast shows an average price of $312.76 with a 1244.6% ROI and bullish sentiment, with a max of $530.77.
Current price is $23.26 and market cap is $1.71B, with a rank of 2077.
Zymeworks Inc. Community Discussion
0Share your Zymeworks Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.